Oral wellness brand Salt Oral Care has picked up $1 million in pre-Series A funding round from Lotus Holdings (Lotus Herbals Family Office). The investment will be executed in two tranches, with the ...

In type 1 diabetes ... and gauge for various sizes of needles and syringes. Barrel size (syringe fluid volume) Insulin units Needle length Needle gauge 0.3 mL 30 units of insulin 3/16 inch ...

oral NLRP3 inflammasome inhibitor NT-0796 to augment existing GLP-1 receptor agonist (GLP-1RA) obesity therapies to deliver enhanced weight loss and sustained weight management. These data, published ...

The Company also announced the acceptance of an abstract, by our partner GenFleet Therapeutics, for rapid oral presentation of the preliminary dose escalation phase of the Phase 1/2 study of VS-7375 ...

This analysis will break down what these results mean for Eli Lilly’s positioning in the red-hot GLP-1 market. Thus, developing an oral GLP-1 medication could significantly increase adoption ...

The impressive data confirmed orforglipron as a frontrunner in the race to introduce the first oral glucagon-like peptide-1 (GLP-1) receptor agonist to the market, with its potential as a convenient ...

LLY’s orforglipron is an investigational, once-daily small-molecule oral GLP-1 receptor agonist that can be administered at any time of the day without restrictions on food and water intake.

Orforglipron significantly reduced HbA1c levels by 1.3% (3mg), 1.6% (12mg), and 1.5% (36mg) compared with 0.1% in the placebo arm. Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor ...

Orforglipron, Eli Lilly’s investigational oral glucagon-like peptide 1 receptor agonist (GLP-1 RA), achieved positive phase 3 results for both A1c and weight loss, according to top-line data ...